Cytokineinduced killer (CIK) cells, stimulated by multiple cytokines, are a group of heterogeneous cells with antitumor activity [1] . CIK cells express two types of membrane proteins, CD3 and CD5, and display both powerful antitumor ability of T lymphocytes and major histocompatibility complex (MHC) with restricted killing tumor cell capacity of natural killer cells. CIK cells have the advantages of high cytotoxicity, fast proliferation, and independent of multidrug resistance of tumor cells [2, 3] . Dendritic cells (DCs), as main antigen presenting cells (APC), present tumor antigen to T lymphocytes, generate cytotoxic T lymphocyte (CTL) response, and induce antitumor immune response [4] . In previous study, through coculturing autologous DCs with CIK cells, autologous DCs significantly increased the proliferation ability of CIK cells and enhanced their antitumor activity [5] . Treatment with autologous DCCIK cells has displayed well clinical application prospect for many types of cancers, such as chronic myeloid leukemia, liver cancer, colon cancer, kidney cancer, and breast cancer [6, 7] . In this study, we cocultured DCs from healthy adult children of cancer patients with autologous CIK cells from patients to generate semiallogeneic DCCIK cells. In addition, we compared the antitumor abilities of autologous CIK cells, DCCIK cells, and semiallogeneic DCCIK cells to explore the most effective antitumor adoptive immunotherapy approach.
Leukemia cell line (K562), renal cancer cell line (ACHN), and liver cancer cell lines (HepG2 and Hep3B) were purchased from Shanghai Chinese Academy of Science Committee. Recombinant human interleukin (IL)4, granulocyte macrophage colonystimulating factor (GMCSF) and IL2 were purchased from Biosource. Fetal calf serum (FCS) and RPMI1640 were purchased from GIBCO. Mouse antihuman monoclonal antibodies, APCCD3, PECD4, FITCCD8 and CD56, were purchased from BD Biosource. LDH assay kit was purchased from Promega. Brefeldin A (BFA) was from Ebioscience. Membrane broken medium was purchased from Ebioscience. 5,6carboxyfluorescein diacetate succinimidy ester (CFSE) was purchased from Molecular Probes. Annexin V apoptosis kit was purchased from Bender MedSystems. Flow cytometry was purchased from Becton Dickinson.
Fifty millilitre of peripheral blood was collected from one patient with renal cancer, two patients with lung cancer, and one patient with maxillary squamous cell carcinoma and their children, respectively. Peripheral blood mononuclear cells (PBMC) were isolated by lymphocyte separation medium. Cells were cultured in RPMI1640 containing 5% FCS and adhered for 2 h. Suspended cells were removed and induced to CIK cells. Adherent cells were cultured using DC medium (RPMI1640 containing 5% FCS, 100 ng/mL of GM鄄 CFS, and 30 ng/mL of IL4). After 24 h, mouse anti human CD3 monoclonal antibody (final concentration was 150 ng/mL), 1500 units/mL of IL2, and 1.5 ng/mL of IL1琢 were added to CIK cells and cultured at 37益 in 5% CO 2 incubator. On the sixth day, another 500 ng of TNF琢 were added to DCs to induce maturation. On the 7th day, CIK cells and autologous DCs or allogeneic DCs were mixed according to a ratio of 20:1 and cultured for another 7 days.
Purification of human renal carcinoma cells and primary culture: renal carcinoma tissues were excised from patients and digested by type IV collagenase to produce single cell suspension. Highly purified renal carcinoma cells were isolated using a method established previously by our lab. Isolated cells as well as K562, ACHN, HepG2, and Hep3B were cultured in RPMI1640 containing 10% FCS at 37益 in 5% CO 2 incubator.
Autologous CIK cells, autologous DCCIK cells, and semiallogeneic DCCIK cells were incubated with CD3, CD4, CD8, CD25 and CD56 antibodies for 30 min. Cells were washed by PBS, fixed by 2% of paraformaldehyde, and analyzed by flow cytometry.
CIK cells cultured were collected on day 7, washed and resuspended with RPMI1640, and incubated for 10 min at 37益 after adding CFSE (final concentration was 1 滋 mol/L). Cells were washed twice by PBS. Labeled T lymphocytes and DCs were mixed according to the ratio of 20:1 and cultured on a 48well plate. Medium was changed every day (half volume). After 6 days, cells were collected and analyzed by flow cytometry.
Autologous CIK cells, autologous DCCIK cells, and semiallogeneic DCCIK cells were collected, resuspened with PBS, and double stained with Annexin V/PI for flow cytometry analysis.
Autologous CIK cells, autologous CDCIK cells, and allogeneic DCCIK cells were mixed respectively with leukemia cell line (K562), primary renal carcinoma cells, ACHN cells, and live cancer cell lines (HepG2 and BEL7402) according to the ratios of 30:1, 10:1 and 3:1. CIK cells were as negative control. LDH assay was used to measure the cytotoxicity of CTL.
AntiCD3 and CD28 antibodies (1 滋 g/mL) were added to T lymphocytes and cells were incubated for 1 h. Then BFA was added and cells were cultured for another 5 h. T lymphocytes were collected, washed once by PBS, and resuspended with 100 滋 L of PBS. FITCantiCD8 and PE antiCD4 monoclonal antibodies were added and cells were incubated on ice for 30 min. Cells were washed once by PBS, fixed by 2% paraformaldehyde on ice, then washed once by PBS, and incubated for 10 min at room temperature after membrane broken medium was added. APCantiIFN酌 and APCantiIL4 monoclonal antibodies were added directly to membrane broken medium and cells were incubated on ice for 30 min. Then cells were washed once by PBS, fixed by 2% paraformaldehyde, and analyzed by flow cytometry.
Two independent samples were calculated by test. SPSS10.0 software was applied for data analysis. A value of ＜ 0.05 was considered as significantly different. (Table 1) . We used CFSE assay to examine the proliferation capacity of autologous CIK cells, autologous DCCIK cells, and semiallogeniec DCCIK cells. As showed in Figure 4A , the proliferation rates of these three types of cells from renal carcinoma patients were 5.78%, 13.1%, and 34.2%, respectively. Data from patients with lung cancer and maxillary squamous carcinoma also revealed that the proliferation capacity of autologous DCCIK cells and semiallogeneic DCCIK cells were higher than that of CIK, cytokine鄄 induced killer; DC鄄 CIK, dendritic cells鄄 CIK. We applied Annexin V/PI double staining to test the cellular apoptosis of autologous CIK cells, autologous DCCIK cells and semiallogeneic DCCIK cells. As showed in Figure 5 , autologous CIK cells cultured for 14 days generated 10.2% of apoptotic cells, while autologous DCCIK cells and semiallogeneic DCCIK cells generated 6.6% and 6.2% of apoptotic cells respectively.
With the characteristics of high antitumor activity, broad spectrum of tumor sensitivity and sensitive to multiple鄄 drug resistant tumors, CIK cells are considered to be safe and effective heterogenic cells. DCs are the most effective antigen presenting cells. Mature DCs present tumor antigen through type II histocompatibility antigen (MHCII), resisting the immune escape of tumor cells [4] . Previous studies have shown that cocultured CIK cells and DCs generate antitumor effective cells (DCCIK cells) [6, 7] . In this study, we compared the autologous CIK cells, autologous DCCIK cells, and semiallogeneic DCCIK cells. We found that semiallogeneic DCCIK cells significantly enhanced the antitumor activity, increased the proliferation capacity of CIK cells, improved the ratios of CD3 After chemotherapy and radiotherapy, the patients with advanced cancer often appear WBC reduction, anemia and other serious side effects. Therefore, repeated blood is not allowed. The number of monocytes per mL in peripheral blood of patients is less than healthy adults. In addition, the number of DCs induced by monocytes is reduced and the biological activity of DCs decreases [8] . However, the number and biological activity of DCs induced by monocytes in peripheral blood from healthy children of patients are normal. Moreover, DCs stimulate the proliferation and antitumor activity of CIK cells through secreting cytokines such as IL12 and IFN酌 [9] . DCs with high activity and The apoptosis was quantified on day 3 with an annexin V and propidium iodide viability assay. originating from hemizygous produce higher level of costimulatory factors, IL12, and other cytokines, enhancing the cytotoxicity and proliferation rate of CIK cells [5, 10] . Compared with autologous DCs, as allogeneic cells, hemizygous DCs have unique advantages. Firstly, tumor cells induce immune tolerance to tumor antigen in patients.
Thus, the effect of immune system is limited. In addition, the damage caused by radiotherapy and chemotherapy also reduce immune system functions. As a danger signal, semiallogeneic DCs from healthy children of patients can stimulate immune response in patients [11, 12] , induce cytokines secretion [13, 14] , and enhance antitumor ability. Secondly, the + cells (inhibitory cells) [17] , enhancing the antitumor ability.
Previous clinical studies and in vitro experimental data have shown that application of cellular immunotherapy associated with allogeneic DCs shows no side effects and self immune response [1822] . Compared with allogeneic DCs, semiallogeneic DCs from children of patients express MHC molecules of patients themselves and match with MHC class I molecules [23] , which prevent the risk of antihost immunologic rejection due to reinjection of allogeneic cells, and enhance the safety of the treatment. Thus, application of semiallogeneic DCCIK cells is a more safety and effective cellular immunotherapy [22, 2426] . In conclusion, compared with autologous CIK cells and autologous DCCIK cells, semiallogeneic DCCIK cells not only significantly enhance the immune response, but also display better security in clinical application, providing a new method for adoptive cellular immunotherapy. Semialloge鄄 neic DCCIK cells show broad clinical application and play an important role in antitumor immunotherapy. The existence of cancer stem cells (CSCs) or stem鄄 like cancer cells (SLCCs) is regarded as the cause of tumor formation and recurrence. However, the origin of such cells remains controversial with two competing hypotheses: CSCs are either transformed from tissue adult stem cells or dedifferentiated from transformed progenitor cells. Compelling evidence has determined the chromosomal aneuploidy to be one of the hallmarks of cancer cells, indicating genome instability plays an important role in tumorigenesis, for which CSCs are believed to be the initiator. To gain direct evidence that genomic instability is involved in the induction of SLCCs, we utilized multiple approaches to enhance genomic instability and monitored the percentage of SLCC in cultured cancer cells. Using side population (SP) cells as a marker for SLCC in human nasopharyngeal carcinoma (NPC) and CD133 for human neuroblastoma cells, we found that DNA damage inducers, UV and mitomycin C were capable of increasing SP cells in NPC CNE鄄 2 and neuroblastoma SKN鄄 SH cells. Likewise, either overexpression of a key regulator of cell cycle, Mad2, or knock down of Aurora B, an important kinase in mitosis, or Cdh1, a key E3 ligase in cell cycle, resulted in a significant increase of SP cells in CNE鄄 2. More interestingly, enrichment of SP cells was observed in recurrent tumor tissues as compared with the primary tumor in the same NPC patients. Our study thus suggested that, beside transformation of tissue stem cells leading to CSC generation, genomic instability could be another potential mechanism resulting in SLCC formation, especially at tumor recurrence stage.
